PATENT CLAIM ANALYSIS

Application Number: 16017781
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["514", "247000"]

Abstract:
Disclosed are methods for treating disorders associated with dopamine receptor activity. In some embodiments, the disclosed methods include assaying the nucleic acid from a subject for the genotype of the variable number tandem repeats (VNTR) polymorphism in the dopamine transporter DAT1/SLC6A3 gene, wherein when one or two alleles for 9 tandem repeats is detected a dopamine partial agonist is administered to the subject; and wherein when two alleles for 10 tandem repeats is detected a dopamine modulator is not administered to the subject. Also provided are methods for treating disorders associated with dopamine receptor activity that include genotyping a subject with respect to a COMT polymorphism, a DRD2 polymorphism, a 48-base-pair VNTR polymorphism in DRD4 exon 3, and/or a ANKK1 TaqA1 polymorphism, and methods for detecting susceptibility to dopamine modulator therapy for conditions associated with dopamine receptor activity.

Claim (Index 9):
A method for detecting a susceptibility to a dopamine partial agonist therapy in a subject suffering from or at risk for developing a disorder associated with dopamine receptor activity, the method comprising:\n (a) obtaining a biological sample from the subject; and (b) performing or having performed one or more genotyping assays on a nucleic acid sample isolated from the subject to determine the subject's genotype with respect to a variable number tandem repeats (VNTR) polymorphism in a dopamine transporter DAT1/SLC6A3 gene, an rs4680 polymorphism in a DA-catabolizing enzyme catechol-O-methyltransferase (COMT) gene, an rs1076560 polymorphism in a D 2  receptor (DRD2) gene, a 48-base-pair VNTR polymorphism in a D 4  receptor (DRD4) gene, and/or an rs1800497 polymorphism in an ankyrin repeat and kinase domain containing 1 (ANKK1) gene, wherein detection of at least one allele for 9 tandem repeats of the DAT1/SLC6A3 VNTR or four or more of (1) a 9 tandem repeat allele of the DAT1/SLC6A3 VNTR; (2) a COMT A allele of the rs4680 polymorphism; (3) a 48-base-pair VNTR in DRD4 exon 3 allele; and (4) a DRD2 T allele of the rs1076560 polymorphism, an ANKK1 TaqA1 A allele of the rs1800497 polymorphism, or both, indicates that the subject is susceptible to a dopamine partial agonist therapy.

Metadata:
- Claim Count in Document: 39.0
- Percentile: 94.0
- Lexical Diversity: 2.0
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13880694', '14796989', '10170356', '09632838', '13739970']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7757374077632011
- 35 USC 102 Novelty (BERT): 0.5726860425736812
- Combined Prediction Score: 0.7554322712442492
- Mean Citation Score: 395.189422
- Max Citation Score: 471.44687000000016
- Similarity Product: 369.5649639698626

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test